Table 1 Top title and abstract terms in each major division
Division | No. of items | Top terms | Youngest terms | Most cited terms |
|---|---|---|---|---|
1. Macro-economic evaluation (dark blue) | 1412 | Policy | Percentage point | Endogeneity |
Health care | Causal effect | Poor health | ||
Demand | Pandemic | Income group | ||
Income | Spillover/ spillover effect | Economic growth | ||
Market | Medicaid expansion | Economic analysis | ||
Self | Affordable care act (ACA) | National longitudinal survey | ||
Incentive | Exogenous valuation | Behavioural risk factor surveillance | ||
Provider | Universal health coverage | Binge drinking | ||
Utilization | Public health insurance | Job loss | ||
Behaviour | Channel | Social network | ||
2. Micro-economic evaluation (green) | 879 | Cost-effectiveness | Year time horizon/ lifetime horizon | Long term survival |
Life year | Deterministic | Discontinuation | ||
QALY/ QALYs | Hazard ratio | Probabilistic analysis | ||
Incremental cost | Scenario analysis | Randomised clinical trial | ||
Trial | State transition model | Cost-effectiveness acceptability curve | ||
Sensitivity analysis | Hepatitis C Virus/ HCV | Ulcer | ||
Markov model | Model input | Mixed treatment comparison | ||
ICER | Patients | Natural history | ||
Utility analysis | T2DM | Individual patient data | ||
Time horizon | Credible interval | Additional QALY | ||
3. Measurement and valuation of outcomes (light blue) | 594 | Preference | Discrete choice experiment/ DCE/ DCEs | Standard gamble |
Health state | Value set | EQ-5D | ||
Validity | Dimensional questionnaire | SF-6D | ||
Respondent | Level EuroQol/ EQ-5D-3L | Descriptive system | ||
Valuation | Generic preference | Experimental design | ||
Questionnaire | Predictive accuracy | Functioning | ||
Instrument | Data quality | Content validity | ||
Discrete choice experiment | Map/ mapping | Approximation | ||
Dimension | Health state utility value | Health state utility | ||
Item | Severity level | Index value | ||
4. Monitoring mechanisms (evaluation) (light grey) | 391 | Systematic review | Systematic review | Outcomes research |
Appraisal | Health technology assessment/ HTA | Reporting | ||
Health technology assessment | Econlit | Checklist | ||
Guidance | Stakeholder | Statement | ||
Economic model | Pubmed/ Embase | Good practice | ||
Transparency | HTA agency | Meeting | ||
Stakeholder | Website | Pharmacoeconomics | ||
Description | Hungary | International society/ ISPOR | ||
Vaccination | Data extraction | Statistical approach | ||
Medline/ Embase | Cochrane library | Developer | ||
5. Guidance and appraisal (dark grey) | 240 | Pound | Care excellence | Critique |
National Institute/ NICE | Overall survival | Clinical evidence | ||
Manufacturer | Network meta-analysis | Indirect treatment comparison | ||
Company | Progression free survival | Dissemination | ||
Centre | ERG | Network meta-analysis | ||
Submission | NICE single technology appraisal | Critical review | ||
Care excellence | Patient access scheme | Submission | ||
Overall survival | Independent evidence review group | Â | ||
NHS | Cost effectiveness evidence | Â | ||
Comparator | Appraisal committee | Â |